34551-19-4

Basic information

• Product Name: (6-CHLORO-BENZOTHIAZOL-2-YL)-METHYL-AMINE
• Synonyms: (6-CHLORO-BENZOTHIAZOL-2-YL)-METHYL-AMINE;2-Benzothiazolamine,6-chloro-N-methyl-(9CI);6-Chloro-N-Methyl-2-benzothiazolaMine
• CAS NO: 34551-19-4
• Molecular Formula: C8H7ClN2S
• Molecular Weight: 198.67258
• Product Categories: BENZOTHIAZOLE
• Mol File: 34551-19-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 307.096 °C at 760 mmHg
• Flash Point: 139.527 °C
• Appearance: /
• Density: 1.443 g/cm³
• CAS DataBase Reference: (6-CHLORO-BENZOTHIAZOL-2-YL)-METHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (6-CHLORO-BENZOTHIAZOL-2-YL)-METHYL-AMINE(34551-19-4)
• EPA Substance Registry System: (6-CHLORO-BENZOTHIAZOL-2-YL)-METHYL-AMINE(34551-19-4)

Safety Data

• Hazardous Substances Data: 34551-19-4(Hazardous Substances Data)

Usage

Uses

6-Chloro-N-methyl-2-benzothiazolamine is used as an antituberculous agent.

Upstream product

• 95-24-9 6-chloro-2-aminobenzothiazole 
• 106-47-8 4-chloro-aniline 
• 67-56-1 methanol 
• 3622-23-9 2,6-dichloro-1,3-benzothiazole 
• 74-89-5 methylamine 
• 2131-55-7 4-Chlorophenyl isothiocyanate 
• 13078-27-8 (4-chloro-phenyl)-[1,2,3,4]thiatriazol-5-yl-amine 
• 2740-97-8 1-(4-chloro-phenyl)-3-methyl-thiourea 
• 7726-95-6 bromine 
• 34551-27-4 (4-chloro-phenyl)-(4-methyl-4H-[1,2,3,4]thiatriazol-5-ylidene)-amine 
• 77-78-1 dimethyl sulfate 

Relevant articles and documents

Synthesis, Type II diabetes inhibitory activity, antimicrobial evaluation and docking studies of indeno[1,2-c]pyrazol-4(1H)-ones

We report a convenient and efficient synthesis of indeno[1,2-c]pyrazol-4(1H)-ones (4a?o) by the reaction of a variety of 2-acyl-(1H)-indene-1,3(2H)-diones (1) and 2-hydrazinylbenzo[d]thiazole/2-hydrazinyl-6-substitutedbenzo[d]thiazoles (2) in the presence of glacial acetic acid in good yields. The structure of the compounds thus prepared were confirmed by analytical and spectral (FT-IR, 1H NMR, 13C NMR, and HRMS) techniques. All the synthesized indeno[1,2-c]pyrazol-4(1H)-ones (4a?o) were assayed for their in vitro Type II diabetes inhibitory activity by using Acarbose as standard drug and in vitro antimicrobial activity utilizing Streptomycin and Fluconazole as reference drugs. Among the synthesized derivatives, 4e (IC50 = 6.71 μg/mL) was found to be more potent against α-glucosidase enzyme as compared with the standard Acarbose (IC50 = 9.35 μg/mL) and 4i (IC50 = 11.90 μg/mL) exhibited good inhibitory activity against α-amylase enzyme as compared with the standard Acarbose (IC50 = 22.87 μg/mL). Also, all the titled compounds showed good antimicrobial activity. In addition, in vitro α-glucosidase and α-amylase inhibition were supported by docking studies performed on the derivatives 4e and 4o, respectively. [Figure not available: see fulltext.].

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.